Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T94493
(Former ID: TTDI01651)
|
|||||
| Target Name |
Human immunodeficiency virus Adenovector Ad35 (HIV Ad35)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Human immunodeficiency virus disease [ICD-11: 1C60-1C62] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | VRC-HIVDNA016-00-VP | Drug Info | Phase 2 | Human immunodeficiency virus infection | [2] | |
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00123968) Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults. U.S. National Institutes of Health. | |||||
| REF 2 | ClinicalTrials.gov (NCT00498056) Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa. U.S. National Institutes of Health. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.